

Where can I find the CHMP recommendation on granting a marketing authorisation for VAZKEPA® (icosapent ethyl) to reduce the risk of cardiovascular events in patients at high cardiovascular risk?

On January 29, 2021, the CHMP published a highlights summary of its recent meeting, including reference to its favorable recommendation opinion on Amarin's drug, icosapent ethyl [here](#).

On February 1, 2021 CHMP announced the full opinion documentation related to its recommendation [here](#).

For more information, please refer to the Amarin press release published January 29, 2021 titled, AMARIN RECEIVES POSITIVE CHMP OPINION FOR ICOSAPENT ETHYL FOR CARDIOVASCULAR RISK REDUCTION.

Dated: February 1, 2021